MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial

We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular lymphoma (FL) in the randomized GADOLIN trial (NCT01059630). Patients received obinutuzumab (G) plus bendamustine (Benda) induction followed by G maintenance, or Benda in...

Descripción completa

Detalles Bibliográficos
Autores principales: Pott, Christiane, Sehn, Laurie H., Belada, David, Gribben, John, Hoster, Eva, Kahl, Brad, Kehden, Britta, Nicolas-Virelizier, Emmanuelle, Spielewoy, Nathalie, Fingerle-Rowson, Guenter, Harbron, Chris, Mundt, Kirsten, Wassner-Fritsch, Elisabeth, Cheson, Bruce D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214251/
https://www.ncbi.nlm.nih.gov/pubmed/31462735
http://dx.doi.org/10.1038/s41375-019-0559-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214251/
https://www.ncbi.nlm.nih.gov/pubmed/31462735
http://dx.doi.org/10.1038/s41375-019-0559-9

Ejemplares similares